182 related articles for article (PubMed ID: 19966852)
41. In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis.
Guo H; Cooper S; Friedman AD
PLoS One; 2016; 11(3):e0150809. PubMed ID: 26937964
[TBL] [Abstract][Full Text] [Related]
42. Cell-type-specific activation and repression of PU.1 by a complex of discrete, functionally specialized cis-regulatory elements.
Zarnegar MA; Chen J; Rothenberg EV
Mol Cell Biol; 2010 Oct; 30(20):4922-39. PubMed ID: 20696839
[TBL] [Abstract][Full Text] [Related]
43. C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment.
Yeamans C; Wang D; Paz-Priel I; Torbett BE; Tenen DG; Friedman AD
Blood; 2007 Nov; 110(9):3136-42. PubMed ID: 17671233
[TBL] [Abstract][Full Text] [Related]
44. [Expression of NF-kappaB mRNA in acute myeloid leukemia].
Liu M; Wei XD; Lü XD; Fan RH; Yin QS; Zhou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):359-62. PubMed ID: 20416168
[TBL] [Abstract][Full Text] [Related]
45. PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.
Verbiest T; Bouffler S; Nutt SL; Badie C
Carcinogenesis; 2015 Apr; 36(4):413-9. PubMed ID: 25750172
[TBL] [Abstract][Full Text] [Related]
46. Cooperation between PU.1 and CAAT/enhancer-binding protein beta is necessary to induce the expression of the MD-2 gene.
Tissières P; Araud T; Ochoda A; Drifte G; Dunn-Siegrist I; Pugin J
J Biol Chem; 2009 Sep; 284(39):26261-72. PubMed ID: 19632992
[TBL] [Abstract][Full Text] [Related]
47. Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.
Kapelko-Słowik K; Urbaniak-Kujda D; Wołowiec D; Jaźwiec B; Dybko J; Jakubaszko J; Słowik M; Kuliczkowski K
Postepy Hig Med Dosw (Online); 2013 Jun; 67():553-9. PubMed ID: 23752607
[TBL] [Abstract][Full Text] [Related]
48. Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts.
Durual S; Rideau A; Ruault-Jungblut S; Cossali D; Beris P; Piguet V; Matthes T
Leukemia; 2007 May; 21(5):1050-9. PubMed ID: 17361223
[TBL] [Abstract][Full Text] [Related]
49. Early B-cell factor 1 (EBF1) is critical for transcriptional control of SLAMF1 gene in human B cells.
Schwartz AM; Putlyaeva LV; Covich M; Klepikova AV; Akulich KA; Vorontsov IE; Korneev KV; Dmitriev SE; Polanovsky OL; Sidorenko SP; Kulakovskiy IV; Kuprash DV
Biochim Biophys Acta; 2016 Oct; 1859(10):1259-68. PubMed ID: 27424222
[TBL] [Abstract][Full Text] [Related]
50. hnRNP K in PU.1-containing complexes recruited at the CD11b promoter: a distinct role in modulating granulocytic and monocytic differentiation of AML-derived cells.
Nika E; Brugnoli F; Piazzi M; Lambertini E; Grassilli S; Bavelloni A; Piva R; Capitani S; Bertagnolo V
Biochem J; 2014 Oct; 463(1):115-22. PubMed ID: 25005557
[TBL] [Abstract][Full Text] [Related]
51. The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis.
Hoogenkamp M; Krysinska H; Ingram R; Huang G; Barlow R; Clarke D; Ebralidze A; Zhang P; Tagoh H; Cockerill PN; Tenen DG; Bonifer C
Mol Cell Biol; 2007 Nov; 27(21):7425-38. PubMed ID: 17785440
[TBL] [Abstract][Full Text] [Related]
52. PU.1 is a lineage-specific regulator of tyrosine phosphatase CD45.
Anderson KL; Nelson SL; Perkin HB; Smith KA; Klemsz MJ; Torbett BE
J Biol Chem; 2001 Mar; 276(10):7637-42. PubMed ID: 11114304
[TBL] [Abstract][Full Text] [Related]
53. The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1.
Jenal M; Batliner J; Reddy VA; Haferlach T; Tobler A; Fey MF; Torbett BE; Tschan MP
Leukemia; 2010 May; 24(5):1073-6. PubMed ID: 20200559
[No Abstract] [Full Text] [Related]
54. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.
Will B; Vogler TO; Narayanagari S; Bartholdy B; Todorova TI; da Silva Ferreira M; Chen J; Yu Y; Mayer J; Barreyro L; Carvajal L; Neriah DB; Roth M; van Oers J; Schaetzlein S; McMahon C; Edelmann W; Verma A; Steidl U
Nat Med; 2015 Oct; 21(10):1172-81. PubMed ID: 26343801
[TBL] [Abstract][Full Text] [Related]
55. The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor.
Heydemann A; Juang G; Hennessy K; Parmacek MS; Simon MC
Mol Cell Biol; 1996 Apr; 16(4):1676-86. PubMed ID: 8657143
[TBL] [Abstract][Full Text] [Related]
56. Ikaros represses and activates PU.1 cell-type-specifically through the multifunctional Sfpi1 URE and a myeloid specific enhancer.
Zarnegar MA; Rothenberg EV
Oncogene; 2012 Oct; 31(43):4647-54. PubMed ID: 22231443
[TBL] [Abstract][Full Text] [Related]
57. Regulation of the PU.1 gene by distal elements.
Li Y; Okuno Y; Zhang P; Radomska HS; Chen H; Iwasaki H; Akashi K; Klemsz MJ; McKercher SR; Maki RA; Tenen DG
Blood; 2001 Nov; 98(10):2958-65. PubMed ID: 11698277
[TBL] [Abstract][Full Text] [Related]
58. A developmentally controlled competitive STAT5-PU.1 DNA binding mechanism regulates activity of the Ig κ E3' enhancer.
Hodawadekar S; Park K; Farrar MA; Atchison ML
J Immunol; 2012 Mar; 188(5):2276-84. PubMed ID: 22279106
[TBL] [Abstract][Full Text] [Related]
59. AML-1, PU.1, and Sp3 regulate expression of human bactericidal/permeability-increasing protein.
Lennartsson A; Pieters K; Ullmark T; Vidovic K; Gullberg U
Biochem Biophys Res Commun; 2003 Nov; 311(4):853-63. PubMed ID: 14623259
[TBL] [Abstract][Full Text] [Related]
60. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
Aivalioti MM; Bartholdy BA; Pradhan K; Bhagat TD; Zintiridou A; Jeong JJ; Thiruthuvanathan VJ; Pujato M; Paranjpe A; Zhang C; Levine RL; Viny AD; Wickrema A; Verma A; Will B
Blood Cancer Discov; 2022 Sep; 3(5):444-467. PubMed ID: 35820129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
